title: [Prophylaxsis against recurrance of hepatitis B virus after liver transplantation].
abstract: OBJECTIVE
  To summarize the clinical data in preventing HBV recurrence after liver transplantation and explore a optimal individual protocol in prophylaxis of HBV recurrence.
  
  
  METHODS
  We retrospected outcomes in 195 recipients who underwent a liver transplantation for HBV-related liver disease between June 2004 and July 2008. According to the anti-virus protocol these recipients are divided into two groups as following: group A received a protocol of combination treatment of lamivudine with HBIG, and group B with combination treatment of adefovir with HBIG. With mean follow-up of 23.7 months, HBV recurrent rate was observed in overall and each group separately.
  
  
  RESULTS
  A total of 195 liver transplant recipients were identified that met the study criteria. At the sixth and eleventh month after operation, HBV recurrence appeared in 2 recipients, each in two groups, which were due to LAM cessation and HBV mutation respectively. Recurrent rate was 0.6% in group A, 3.7% in group B and 1% in total. There was no significant difference in HBV recurrent rate between group A and B.
  
  
  CONCLUSIONS
  Lamivudine combined with HBIg should be considered as a reliable method in preventing HBV recurrence after liver transplantation. Better outcomes can be achieved by individual anti-virus protocol and HBIg administration according to HBV status in recipient.
authors.affiliation: Department of Surgery, Beijing You' An Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Ju-shan
authors.initials: JS
authors.lastname: Wu
authors.forename: Shi-chun
authors.initials: SC
authors.lastname: Lu
authors.forename: Meng-long
authors.initials: ML
authors.lastname: Wang
authors.forename: Ren-pin
authors.initials: RP
authors.lastname: Xia
authors.forename: Qing-liang
authors.initials: QL
authors.lastname: Guo
authors.forename: Da-ming
authors.initials: DM
authors.lastname: Gao
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Ning
authors.initials: N
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019072:Antibiotic Prophylaxis; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control* / Q000601:surgery; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D019259:Lamivudine